Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PETRANHA: saruparib with new hormonal agents in metastatic prostate cancer
2023-508536-64-00Phase 2Authorised
- Sponsor
- AstraZeneca
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label trial of saruparib in Metastatic Prostate Cancer (mPC), prostate cancer (PCa) and metastatic castration-resistant prostate cancer (mCRPC) (4 arms), sponsored by AstraZeneca. Primary endpoints: Number of participants with adverse events and serious adverse events, Number of participants with dose-limiting toxicities and 1 more. Planned start Feb 2024; status: authorised.
02
Drugs
saruparib
03
Conditions
Metastatic Prostate Cancer (mPC)prostate cancer (PCa)metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2023-508536-64-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508536-64-00.